StockNews.AISignal intelligence
Company intelligence

RAPP

Rapport Therapeutics, Inc. Common Stock · NASDAQ

Price$26.15+1.16% · +$0.30
Market cap1.25BEquity value
P / E-8.6Trailing ratio
Volume316.12KLatest session
Market data

RAPP price chart

TradingView
Related signals
1 min delayed

Browse public RAPP signals with their source context and measured market impact. Open any signal for its permanent analysis page.

RAPPOct 20, 2026-8.04% since signal

Bipolar Mania Trial Meets Endpoints, Signals Phase II Readiness

A bipolar mania therapy demonstrated statistically significant placebo-adjusted improvements at Week 3, with YMRS up 3.1 points (p=0.045) and CGI-BP Severity of Mania up 0.4 points (p=0.024). Meeting both primary and secondary endpoints could de-risk the program and prompt further Phase II/III discussions, potentially supporting near-term investor interest.

View signal analysis
Research

Company intelligence